Analysts/Institutional Investor Meet/Con. Call Updates

Dated: September 26, 2026 National Stock Exchange of India Limited BSE Limited Symbol: NSE: GRANULES; BSE: 532482 Sub: Intimation of Schedule of Webinar Dear Sir/mam, Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, IIFL Capital is organizing a webinar on September 29, 2026, at 4:30 p.m. to discuss the Company’s transformation journey. The webinar details and registration link are enclosed with this letter. Thanking You. Yours sincerely, For GRANULES INDIA LIMITED CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER) Encl: Details of the Webinar REGISTERED OFFICE Granules India Limited CIN: L24110TG1991PLC012471 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India Contact Us: Tel: +91-40-69043500 |Fax: +91-40-23115145| mail@granulesindia.com www.granulesindia.com IIFL EVENTS Granules India 2.0 Comprehensive Transformation Underway Key growth engines: Controlled substances | Complex formulations & injectables | Oncology | FTF opportunities | Peptide CDMO Granules is moving beyond its legacy generics franchise, with formulations now accounting for ~75% of revenue and a sharp reduction in dependence on its legacy-5 portfolio (from ~85% in FY23 to <50% in FY26). The company is targeting further growth through controlled substances, Date: 29th Sep 2026 complex formulations, oncology, first-to-file/Para IV US opportunities and peptide CDMO. Tuesday Time: We invite you to join an exclusive interaction with Granules’ promoter and senior mgmt team to understand: 4:30pm IST, # Controlled substances: Can Granules sustain momentum in a highly 12 noon BST, regulated market where DEA quotas, supply reliability and compliance 7am ET, 7pm HKT create structural barriers? # Complex formulations & injectables: What is the roadmap for more complex products, including potential injectables, and how could these reshape the portfolio and margins? # Oncology: How can Granules monetise its existing gross block, product Register pipeline and potential 180-day exclusivity opportunities from FY28? now! # FTF opportunities: What is the size and quality of Granules’ first- to-file/Para IV pipeline, and where does the company see meaningful opportunities? # Peptide CDMO: How is Granules building its peptide CDMO platform through Senn, what is the opportunity across peptides/oligos/ADCs, and what could drive the targeted USD100m revenue opportunity over the next 4-5 years? # Transformation: How will the evolving business mix translate into revenue growth and margin expansion over the next 3–5 years? Kindly register for the webinar for a focused discussion on the key building blocks of Granules’ next phase of growth.